We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Getein Biotech, Inc.

Getein Biotech, Inc. is a fully integrated in vitro diagnostic company that develops, manufactures and distributes an... read more Featured Products: More products

Download Mobile App





Getein Biotech Demonstrates Rapid Immunofluorescence Quantitative Analyzers for POC Testing

By LabMedica International staff writers
Posted on 25 Jul 2023
Print article
Image: A wide range of benchtop and POC analyzers is being displayed at AACC 2023 (Photo courtesy of Getein Biotech)
Image: A wide range of benchtop and POC analyzers is being displayed at AACC 2023 (Photo courtesy of Getein Biotech)

Getein Biotech, Inc. (Nanjing, China) is showcasing its latest innovations at AACC 2023 including its benchtop immunofluorescence and hematology analyzers as well as its handheld POCT analyzers.

At AACC 2023, Getein is demonstrating the Metis 600 integrated system that provides a suitable solution for immunofluorescence and hematology testing to low-volume laboratories. The combination of immunofluorescence and hematology methodologies in a single system allows for more comprehensive test items to be offered. Metis 600 improves laboratory efficiency through the highest level of automation and accelerates turnaround time for high-volume sample testing. Also on display is the MAGICL 6000 chemiluminescence immunoassay analyzer, a compact and innovative system offering an optimal choice for mid to high-workflow laboratories that need a one-step chemiluminescence solution. Highly productive and compact, this instrument enables fully automated operation and provides the fastest testing speed of any device of its size.

In addition, the company is demonstrating the Getein 1160 immunofluorescence quantitative analyzer - a multi-channel POCT analyzer with four incubation channels and one emergency test channel. It also has a constant test environment with 32℃ to ensure more accurate test results, making it ideal for applications in emergency, critical care (ICU, CCU), outpatient, cardiology, inpatient wards, clinical laboratories, etc. Alongside this, the company is demonstrating the Getein 1100 immunofluorescence quantitative analyzer that is used to measure the concentration of biomarkers in human whole blood, serum, plasma, urine, nasal swab, or saliva samples. The results can be used as an aid in clinical diagnostics of laboratory and point-of-care testing. In addition, Getein is showcasing the CM-400 fully automated clinical chemistry analyzer that is intended to quantitatively analyze chemical components in human serum, plasma, whole blood, urine, and cerebrospinal liquid samples, offering constant throughput of 400 T/h.

Related Links:
Getein Biotech, Inc. 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
RNA Isolation Kits
RNeasy Plus Kits for RNA Isolation
New
HSV-1 Test
Herpes Simplex Virus 1 Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.